Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Not Recruiting

Trial ID: NCT00375830


This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Official Title

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Robert Herfkens
Robert Herfkens

Professor of Radiology (Cardiovascular Imaging), Emeritus

Shreyas Vasanawala, MD/PhD
Shreyas Vasanawala, MD/PhD

William R. Brody Professor of Pediatric Radiology and Child Health


All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).


   - ≥ 18 years old at the time of the drug administration

   - ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
   (PSA) > 10 micrograms/L OR recurrent breast or prostate cancer

   - Capable of complying with study procedures

   - Able to remain still for duration of imaging procedure (about one hour)

   - Written informed consent


   - Pregnant or nursing

   - Metallic implants that contraindicate MRI

   - Renal function impairment that contraindicates MRI


drug: Gadopentetate dimeglumine

drug: Gadofosveset

drug: Gadobutrol

procedure: Bone scan

procedure: Positron Emission Tomography (PET) scan

drug: 18F-Fludeoxyglucose (18F-FDG)

procedure: Computed Tomography (CT) scan

drug: 18F-Sodium Fluoride (18F-NaF)

procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan

drug: 99mTc-methyl diphosphonate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.